

**Remarks**

Applicants have cancelled claims 1- 48 without prejudice to their rights to pursue the subject matter of these claims in other applications. Applicants have added new claims 49 to 57 which redirect the subject matter of the invention towards a single selected gene to diagnose coronary artery disease. As discussed with the Examiner, Applicants have thus shifted the current invention from the disease depression to coronary artery disease. Applicants believe that the newly added claims are examinable without further restriction. Applicants thus respectfully request the Examiner accept the newly amended claims.

Applicant has also amended the title of the pending application to more accurately reflect the subject matter of the newly amended claims.

Claims 49- 57 are pending. Support for the newly added claims is found through the specification and in the originally filed claims. In particular, support for the gene Cytotoxic and Regulatory T cell Molecule (CRTAM) is noted in Table 3L under the RNA accession number NM\_019604.1 with a p value of 0.028892788 and is described in Figure 19, Example 21. No new matter has been added.

In response to the Restriction Requirement dated August 30, 2006, Applicants elect **Group I** and have elected a single combination of "one or more" markers from the tables relevant to the detection of coronary artery disease, namely Table 3L.

As noted, the Applicant has elected the selection of the gene Cytotoxic and Regulatory T cell Molecule (CRTAM) which is found in Table 3L.

A petition for extension of time is attached. However, should any fees be required to ensure consideration of this response, the Commissioner is authorized to charge Deposit Account 04-1105, Reference No. 204231/2055D.

Respectfully submitted,

Date: January 25, 2007

*Amy DeLoux*  
*for*  
Name: Kathleen M. Williams  
Registration No.: 34,380  
Customer No.: 29933

Edwards Angell Palmer & Dodge LLP  
P.O. Box 55874  
Boston, MA 02205  
Tel: 617-239-0100